Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial Geraldine Gebhart , Marleen Keyaerts , Thomas Guiot , Patrick Flamen , Manuel Ruiz-Borrego , Agostina Stradella , Begona Bermejo , Santiago Escriva-de-Romani , Lourdes Calvo Martinez , Nuria Ribelles , Maria Fernandez-Abad , Cinta Albacar , Marco Colleoni , Laia Garrigos , Manuel Atienza de Frutos , Florence Dalenc , Aleix Prat , Frederik Marme , Peter Schmid , Khaldoun Kerrou , Sofia Braga , Petra Gener , Miguel Sampayo-Cordero , Javier Cortes , Jose Manuel Perez-Garcia , Antonio Llombart-Cussac Journal of Nuclear Medicine（2024）
关键词
PHERGain trial, SUV(max )cutoff, chemotherapy deescalation, HER2+early breast cancer
AI 理解论文
溯源树
样例
